Press Release 06.2018: Oncoinvent is pleased to announce that research scientist Elisa Napoli presented Radspherin® research findings earlier this week during the Monday morning Novel Radiochemistry session at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Philadelphia, USA.

Press Release 05.2018: Oncoinvent is pleased to announce today that it has fulfilled the necessary requirements stipulated by the Research Council of Norway and is now eligible to receive 12 MNOK in BIA project funding to help develop its lead product Radspherin®.

Press Release 04.2018: Oncoinvent announced today that the regulatory strategy that will be used in the development of its lead product Radspherin® has been selected.

Press Release 03.2018: Oncoinvent publishes data explaining Radspherin® `s mechanism of action

Press Release 02.2018: Oncoinvent is pleased to announce today that Oncoinvent has been selected to receive BIA project funding from the Research Council of Norway to help develop its lead product Radspherin®.

Press Release 01.2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.

Press Release 08.2017: Oncoinvent held an opening ceremony for its new production and lab facilities today. A total of 40 guests attended the opening.

Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Press Release 06.2017 Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients. In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention. The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.

Press Release 05.2017: Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.